Purchase 500 million yuan worth of financial products from REMEGEN (09995).
Rongchang Biotechnology (09995) announced that on October 15, 2025, the company entered into an agreement with the Yantai Branch of Shanghai Pudong Development Bank...
REMEGEN (09995) announced that on October 15, 2025, the company entered into a Wealth Management Product Agreement with the Shanghai Pudong Development Bank Yantai Branch. According to this agreement, the company agreed to (1) use 400 million RMB of idle own funds to purchase wealth management products from the Shanghai Pudong Development Bank Yantai Branch, and (2) use 100 million RMB of idle raised funds to purchase wealth management products from the Shanghai Pudong Development Bank Yantai Branch.
Related Articles
US Stock Market Move | Popular Chinese concept stocks collectively rose sharply, with New Oriental Education & Technology Group, Inc. Sponsored ADR (EDU.US) jumping more than 8%.
US Stock Market Move | Gold stock continues to strengthen, Kinross Gold Corporation (KGC.US) rises more than 7%
US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.
US Stock Market Move | Popular Chinese concept stocks collectively rose sharply, with New Oriental Education & Technology Group, Inc. Sponsored ADR (EDU.US) jumping more than 8%.
US Stock Market Move | Gold stock continues to strengthen, Kinross Gold Corporation (KGC.US) rises more than 7%
US Stock Market Move | Omeros Corporation (OMER.US) soars 150% following asset purchase and license agreement with Novo Nordisk A/S Sponsored ADR Class B.
